AbbVie (NYSE:ABBV) Shares Down 1% – Should You Sell?

AbbVie Inc. (NYSE:ABBV) fell 1% during trading on Tuesday. The company traded as low as $261.52 and last traded at $263.5410. Approximately 3,946,828 shares traded hands during mid-day trading, a decline of 39% from the average daily volume of 6,468,157 shares. The stock had previously closed at $266.28.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The FDA approved Juvmo (tavapadon), AbbVie’s once-daily oral treatment for adults with Parkinson’s disease. Juvmo is the first and only selective D1/D5 receptor agonist approved for the condition, and Phase 3 data showed improvements in motor control, daily functioning and “on” time without troublesome dyskinesia. The drug is scheduled to launch in the U.S. in October and could address a Parkinson’s market estimated at more than $5 billion. U.S. FDA Approves AbbVie’s Juvmo
• Positive Sentiment: The approval validates AbbVie’s $8.7 billion Cerevel Pharmaceuticals acquisition and expands its neuroscience portfolio beyond its established immunology and aesthetics franchises. Analysts have suggested Juvmo could eventually become a billion-dollar product. AbbVie’s Cerevel buyout delivers
• Positive Sentiment: AbbVie partnered with Valkai to apply artificial intelligence across targeted clinical-development activities. The collaboration is intended to strengthen AbbVie’s AI capabilities, improve development efficiency and accelerate the delivery of new medicines, supporting longer-term pipeline growth. AbbVie partners with Valkai
• Neutral Sentiment: Brokerages’ average price target is approximately $272.66, modestly above the recent trading level, indicating measured upside expectations rather than a major near-term repricing. AbbVie average target price
• Negative Sentiment: ABBV’s decline following the Juvmo announcement indicates a possible “sell-the-news” reaction. Investors may also be concerned that management expects a slow initial launch, with meaningful revenue contribution dependent on physician adoption, market access and gradual patient uptake. AbbVie stock drops after Juvmo approval

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Leerink Partners boosted their target price on shares of AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Piper Sandler raised their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Citigroup lifted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, Bank of America reiterated a “buy” rating on shares of AbbVie in a research report on Tuesday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $272.66.

AbbVie Stock Down 1.0%

The stock has a 50 day moving average of $257.41 and a 200 day moving average of $233.59. The firm has a market cap of $465.62 billion, a price-to-earnings ratio of 74.45, a P/E/G ratio of 1.19 and a beta of 0.29.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the company earned $2.97 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s dividend payout ratio (DPR) is currently 195.48%.

Insiders Place Their Bets

In other news, EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Institutional Trading of AbbVie

Several institutional investors have recently modified their holdings of ABBV. Ranch Capital Advisors Inc. increased its stake in shares of AbbVie by 37.0% in the first quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock worth $3,238,000 after buying an additional 4,017 shares during the period. Capital Advisors Inc. OK grew its holdings in AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after acquiring an additional 45,132 shares during the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new stake in AbbVie in the 2nd quarter worth $23,557,000. Wedge Capital Management L L P NC increased its position in shares of AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock valued at $33,865,000 after acquiring an additional 9,380 shares during the period. Finally, Mission Wealth Management LP increased its position in shares of AbbVie by 119.1% in the second quarter. Mission Wealth Management LP now owns 69,052 shares of the company’s stock valued at $17,376,000 after acquiring an additional 37,531 shares during the period. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.